Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human CD19-CD22 Targeted T Cells Injection
- Development stage
- Phase 1
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
Human CD19-CD22 Targeted T Cells Injection is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Hrain Biotechnology. It is designed to simultaneously target two B-cell specific antigens, CD19 and CD22, to mitigate the risk of relapse due to antigen escape, a common challenge in single-target CAR-T therapies. This specific formulation is being investigated for patients with refractory or relapsed B-cell malignancies that have central nervous system (CNS) involvement, such as CNS lymphoma and B-cell acute lymphoblastic leukemia. A unique aspect of its clinical development is the dual administration route—intravenous and intrathecal—aimed at overcoming the blood-brain barrier and directly targeting malignant cells within the cerebrospinal fluid and CNS tissues.
- Other names
- CD19/CD22 dual-targeted CAR-T cellsanti-CD19/CD22 CAR-T cellsHuman CD19-CD22 Targeted T Cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on Human CD19-CD22 Targeted T Cells Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human CD19-CD22 Targeted T Cells Injection.